Transgenic mice for the IGF-I pathway, over-expressing IGF-I, IGF-IR, or IRS1 and IRS2 in the mammary gland, all develop breast adenocarcinomas [12,13,48,49]. This evidence concerns the gene IRS2 and breast adenocarcinoma.